Abstract 488P
Background
Glioma, the most common malignancy of the central nervous system, is charactarised by its extensive proliferation and invasion. An increasing number of studies suggest that glioma stem cells (GSCs) are at the root of glioma's difficulty in control, treatment and recurrence. The adhesion molecule integrin α2 (ITGA2) plays an important role in regulating various biological behaviors such as cell migration, growth and differentiation. Previous studies have shown that ITGA2 is closely associated with tumor progression, but the role and mechanism of ITGA2 in regulating glioma progression and stemness remain unclear.
Methods
The gene expression profile of GSCs was analyzed by RNA-seq. ITGA2 expression in glioma tissues was examined by immunohistochemical staining, followed by analysis of the correlation between ITGA2 expression and clinical features. In addition, the effects of lentivirus-mediated RNA interference of ITGA2 on cell proliferation, cell migration, spheroid forming ability and cell stemness specific gene and protein expression in glioma cells were investigated.
Results
The expression level of ITGA2 was significantly increased in GSCs compared to glioma cells. ITGA2 protein expression was increased in high-grade glioma samples. Prognostic analysis showed that patients with high ITGA2 expression had shorter survival. In glioma cells, knockdown of ITGA2 significantly inhibited the proliferation, migration, invasion and spheroid forming ability of glioma cells. TCGA data analysis showed that ITGA2 expression positively correlated with the expression of stem cell-specific genes in gliomas. Knockdown of ITGA2 significantly reduced the expression levels of stem cell-specific genes and proteins in the cells. The molecular mechanism revealed that ITGA2 knockdown inhibited the activation of the AKT signaling pathway. The AKT phosphorylation activator SC79 reversed the reduced sphere-forming ability of glioma cells and the reduced expression levels of stem cell-specific genes and proteins in cells caused by ITGA2 knockdown.
Conclusions
Our findings elucidate the role and molecular mechanism of ITGA2 in regulating glioma progression and stemness, and provide new ideas for basic glioma research and tumor treatment strategies targeting GSCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16
458P - Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Presenter: Diya Jayram
Session: Poster session 16
459P - Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US
Presenter: Jennifer Connelly
Session: Poster session 16
460P - Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Presenter: Zelei Dai
Session: Poster session 16
461P - Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Presenter: Marta Padovan
Session: Poster session 16
462P - Regorafenib for relapsed glioblastoma: Retrospective real-world analysis of a single Institution experience
Presenter: Giulia Rovesti
Session: Poster session 16
463P - Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
Presenter: Madison Sherman
Session: Poster session 16
465P - Surgical intervention association with the development of subsequent dissemination in childhood diffuse intrinsic pontine gliomas (DIPG)
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract
466P - Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Presenter: Olga Regentova
Session: Poster session 16
Resources:
Abstract
467P - Temozolomide potentially postpones the development of subsequent metastases in pediatric diffuse intrinsic pontine glioma (DIPG) patients
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract